Study of AK112 plus chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stage IV non-squamous non-small cell lung cancer with fluid buildup in the chest due to cancer.
- Your cancer should not have certain gene mutations (like EGFR or ALK) that have targeted treatments.
- You must be well enough to care for yourself (ECOG score 0-2) and have a life expectancy of at least 3 months.
- You must have tumors that can be measured on scans, and you must provide a tumor tissue sample.
- You cannot have had prior treatment targeting blood vessel growth (VEGFR) or have certain active infections or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
This trial tests a new combination of an immunotherapy drug (AK112) with standard chemotherapy as the first treatment for people with a certain type of lung cancer that has spread to the brain. It may help control the cancer by boosting your immune system to fight it, and the study will check how well it works and how safe it is.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.